Intas Pharma to acquire Udenyca business from Coherus BioSciences
Raleigh: Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology and critical care therapies, has announced that Intas Pharmaceuticals has signed an agreement to acquire the UDENYCA (pegfilgrastim-cbqv) business from Coherus BioSciences, Inc.
UDENYCA is a pegfilgrastim biosimilar to Neulasta and is typically administered the day after chemotherapy to decrease the incidence of infection as caused by febrile neutropenia. During the 2023 fiscal year, sales of UDENYCA totaled $127.1 million. "When final, the acquisition will expand Accord BioPharma's product portfolio and is expected to position the company for accelerated growth in the biosimilar industry," the release stated.
UDENYCA is a pegfilgrastim biosimilar approved in the United States currently available in three administration options — prefilled syringe (PFS), autoinjector (AI) and on-body injector (OBI) — providing patients and healthcare providers with choice, control and convenience. Since its launch in 2019, over 300,000 patients have been treated with UDENYCA.
"By adding UDENYCA to our growing portfolio of biosimilars, we will strengthen our business footprint in the U.S." said Chrys Kokino, U.S. President of Accord. "With an expanding presence in the market, we can fuel the internal innovation and external expansion needed to deliver more accessible treatment options to patients."
Read also: Intas Pharmaceutical Gets CDSCO Panel Nod To Manufacture, Market Anti-cancer Drug Pertuzumab
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.